Physician profile
Nathan B Richards
NPI 1497968366
$6,958.93
in general payments reported to CMS, 2019-2025
31 companies · $1,451 in 2025
The $1,451 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $473 · 2020: $741 · 2021: $981 · 2022: $1,263 · 2023: $1,029 · 2024: $1,022 · 2025: $1,451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,468 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,467.90 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,549.76 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $860.37 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $532.78 | 2019-2025 | Dupixent |
| Csl Behring | $475.26 | 2019-2025 | Haegarda, Andembry |
| Boehringer Ingelheim Pharmaceuticals, INC. | $392.77 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
| Intuitive Surgical, INC. | $374.85 | 2020 | |
| Genzyme Corporation | $332.04 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $321.09 | 2021-2025 | Takhzyro, Cuvitru |
| Biocryst US Sales Co., LLC | $274.07 | 2021-2025 | Orladeyo |
| Novartis Pharmaceuticals Corporation | $256.31 | 2019-2025 | |
| Pfizer INC. | $231.98 | 2020-2025 | |
| Amgen INC. | $227.40 | 2022-2025 | Tezspire |
| Kaleo, INC. | $197.99 | 2021-2024 | Auvi-Q |
| Teva Pharmaceuticals USA, INC. | $160.38 | 2020-2022 | |
| Genentech USA, INC. | $125.41 | 2021-2024 | Xolair |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $118.64 | 2019-2024 | |
| Pharming Healthcare, INC. | $107.20 | 2022-2025 | Ruconest |
| Alk-Abello, INC | $96.10 | 2020-2022 | |
| Covis Pharma Gmbh | $64.21 | 2021-2022 | |
| Grifols USA, LLC | $45.58 | 2020-2022 | |
| Blueprint Medicines Corporation | $30.89 | 2024-2025 | Ayvakit |
| Octapharma USA, INC. | $29.59 | 2023 | Cutaquig |
| Hikma Pharmaceuticals USA | $21.04 | 2025 | Ryaltris |
| Ars Pharmaceuticals Operations, INC. | $20.66 | 2025 | Neffy |
| Lilly USA, LLC | $19.03 | 2025 | Ebglyss |
| Verona Pharma, INC. | $16.27 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $16.06 | 2023 | |
| Sanofi-Aventis U.S. LLC | $15.50 | 2021 | |
| Shire North American Group INC | $15.49 | 2019 | |
| Mylan Specialty L.P. | $15.36 | 2023 | Yupelri |
| Incyte Corporation | $14.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Richards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.